Literature DB >> 6973500

Intestinal clearance of alpha 1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy.

C Florent, C L'Hirondel, C Desmazures, C Aymes, J J Bernier.   

Abstract

Gastrointestinal loss of plasma is usually measured with radiolabeled macromolecules. These methods are expensive and cumbersome. The use of alpha 1-antitrypsin as an endogenous marker and the determination of alpha 1-antitrypsin fecal clearance enable the diagnosis of protein-losing enteropathy. alpha 1-Antitrypsin is measured in feces and blood by radial immunodiffusion, and the results are expressed as clearance. There is a significant correlation between alpha 1-antitrypsin fecal clearance and 51Cr-plasma protein clearance (r = 0.96, p less than 0.001). The sensibility of alpha 1-antitrypsin test compared to [51Cr] is 93.3%, the specificity is 90%. The positive predictive value is 97.7%, the negative predictive value 75%. We found no alpha 1-antitrypsin in gastric juice of pH below 3. In vitro studies confirmed the destruction of alpha 1-antitrypsin in gastric juice of pH below 3. There is a slight decrease of alpha 1-antitrypsin concentration when stools are incubated at 37 degrees C. In duodenal juice there is a small lessening of alpha 1-antitrypsin concentration after an incubation at 37 degrees C for 1 h. In conclusion, the fecal clearance of alpha 1-antitrypsin seems to be an inexpensive and quite reliable test of protein-losing enteropathy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6973500

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

1.  Protein losing enteropathy in critically ill adult patients with burns: a preliminary report.

Authors:  Balasubramanian Venkatesh; Jenny Gough; David R Ralston; Michael Muller; Stuart Pegg
Journal:  Intensive Care Med       Date:  2003-11-21       Impact factor: 17.440

2.  Detection and quantification of protein-losing enteropathy with indium-111 transferrin.

Authors:  M C de Kaski; A M Peters; D Bradley; H J Hodgson
Journal:  Eur J Nucl Med       Date:  1996-05

3.  Enteral nutrition as a primary therapy for intestinal lymphangiectasia: value of elemental diet and polymeric diet compared with total parenteral nutrition.

Authors:  Kunihiko Aoyagi; Mitsuo Iida; Takayuki Matsumoto; Shotaro Sakisaka
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

4.  Early Impact of Fontan Operation on Enteric Protein Loss.

Authors:  Jyoti K Patel; Kathleen M Loomes; David J Goldberg; Laura Mercer-Rosa; Kathryn Dodds; Jack Rychik
Journal:  Ann Thorac Surg       Date:  2015-12-01       Impact factor: 4.330

5.  Retractile mesenteritis presenting as protein-losing gastroenteropathy.

Authors:  Bahe Rajendran; Donald R Duerksen
Journal:  Can J Gastroenterol       Date:  2006-12       Impact factor: 3.522

6.  Clinical and physiological study of anal sphincter and ileal J pouch before preileostomy closure and 6 and 12 months after closure of loop ileostomy.

Authors:  S Chaussade; S Michopoulos; M Hautefeuille; P Valleur; P Hautefeuille; J Guerre; D Couturier
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

7.  Screening laboratory tests for Crohn's disease.

Authors:  D W Thomas; F R Sinatra
Journal:  West J Med       Date:  1989-02

8.  Protein-losing enteropathy in systemic lupus erythematosus. Diagnosis and monitoring immunosuppressive therapy by alpha-1-antitrypsin clearance in stool.

Authors:  K G Benner; A Montanaro
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

9.  Fecal clearance of alpha1-antitrypsin with lansoprazole can detect protein-losing gastropathy.

Authors:  H Takeda; S Nishise; M Furukawa; R Nagashima; H Shinzawa; T Takahashi
Journal:  Dig Dis Sci       Date:  1999-11       Impact factor: 3.199

Review 10.  Current Role of Blood and Urine Biomarkers in the Clinical Care of Adults with Congenital Heart Disease.

Authors:  Saurabh Rajpal; Laith Alshawabkeh; Alexander R Opotowsky
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.